Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WT1 mRNA-electroporated autologous dendritic cell vaccination in myeloid malignancies and multiple myeloma
2009-015720-28Phase 2Completed
- Sponsor
- Antwerp University Hospital
- Start
- Sep 2009
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of WT1 mRNA dendritic cell vaccine in acute myeloid leukemia (AML), chronic myelogenous leukemia (CML) and multiple myeloma (MM), sponsored by Antwerp University Hospital. Primary endpoints: Immunogenicity of intradermal dendritic cell vaccination and Clinical efficacy. Started Sep 2009; status: completed.
02
Drugs
WT1 mRNA dendritic cell vaccine
03
Conditions
acute myeloid leukemia (AML)chronic myelogenous leukemia (CML)multiple myeloma (MM)
Beyond the preview
Go deeper on 2009-015720-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015720-28.